ACOR

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Research, Therapy, OPEX, Q&A, Conference, GAAP, Acorda Therapeutics, R, Growth, ACOR, Video game, Bank, Cryptocurrency, Broadcasting, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023.
  • For the quarter ended September 30, 2023, the Company reported AMPYRA net revenue of $15.7 million, a 26% decrease compared to $21.1 million for the same quarter in 2022.
  • Research and development (R&D) expenses for the quarter ended September 30, 2023 were $1.2 million, compared to $1.4 million for the same quarter in 2022.
  • Total operating expenses for the quarter ended September 30, 2023 was $30.2 million, compared to $38.5 million for the same quarter in 2022.

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

Retrieved on: 
Monday, November 6, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, PD, Acorda Therapeutics, CNS, Marketing, OFF, Parkinson's disease, ACOR, Therapy, Patient, Pharmaceutical industry

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas).

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas).
  • Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru.
  • It expects to submit additional regulatory filings for approval of INBRIJA in Chile in late 2023 and in Mexico and Brazil in 2024.
  • “We are delighted that Biopas has submitted filings for the approval of INBRIJA in six countries in Latin America, with up to five approvals expected in 2024.

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Neurology, ACOR, Shareholder, SG, Senior, Q&A, Marketing, MIL-PRF-38535, GAAP, Research, 4-Aminopyridine, Patient, Physician, Burns, OPEX, Growth, Acorda Therapeutics, R, Therapy, Cryptocurrency, Video game, Bank, Broadcasting, Finance, Açorda, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023.
  • Research and development (R&D) expenses for the quarter ended June 30, 2023 was $1.6 million, compared to $1.5 million for the quarter ended June 30, 2022.
  • Total operating expenses for the quarter ended June 30, 2023 was $33.3 million, compared to $45 million for the same quarter in 2022.
  • The Company will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results today at 4:30 p.m.

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Retrieved on: 
Wednesday, August 2, 2023
Pharmaceutical, Health, Neurology, COPD, Glaucoma, Mental toughness, Hallucination, Asthma, Psychosis, ACOR, Butyrophenone, Medicine, Education, Wheeze, Friends, Phenothiazine, Somnolence, Fever, Phenelzine, PWP Heavyweight Championship, Dopamine, Açorda, Risperidone, Fighter, Capsule, L-DOPA, Dizziness, Tranylcypromine, Patient, Gambling, Nausea, Confusion, Perspiration, Dyskinesia, Acorda Therapeutics, OFF, Metoclopramide, Upper respiratory tract infection, Therapy, Sleep, Bronchospasm, Family, Saliva, Disease, Pharmaceutical industry, Birth control, Interior design

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.
  • INBRIJA is not to be used by people who have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks.
  • I’m determined to make every day, every moment, count, and to live a full life with my family and friends.
  • The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Tom Burns Elected to the Acorda Therapeutics Board of Directors

Retrieved on: 
Wednesday, June 28, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Bachelor, ACOR, Senior, McAfee, Golden Gate University, CA Technologies, Audit committee, Accounting, Business administration, Santa Clara University, Conner Peripherals, Acorda Therapeutics, Therapy, Master of Business Administration, Mattson Technology, Management

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Tom Burns, Chief Financial Officer at XOMA Corporation, has been elected to its Board of Directors by the stockholders at the Company’s Annual Meeting.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Tom Burns, Chief Financial Officer at XOMA Corporation, has been elected to its Board of Directors by the stockholders at the Company’s Annual Meeting.
  • Jeff Randall, who had served on Acorda’s Board since 2006 and was Chair of the Audit Committee, has rotated off the Board.
  • “Tom is a highly experienced, savvy financial executive, and we are delighted that he has joined our Board.
  • I’m looking forward to working with the Board to continue to build value for our shareholders.”
    John Kelley, Acorda’s Board Chair, added: “On behalf of Acorda’s Board, I want to welcome Tom to the team.

Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement

Retrieved on: 
Monday, June 26, 2023
Health Technology, Pharmaceutical, Health, Neurology, Acorda Therapeutics, ACOR, Therapy, Cryptocurrency, Auction

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).
  • Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.

Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split

Retrieved on: 
Friday, June 2, 2023
Neurology, Biotechnology, Pharmaceutical, Finance, Health, Mental Health, Professional Services, Clinical Trials, CUSIP, Acorda Therapeutics, ACOR, Therapy, Auction, Holding company

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock.
  • The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023.
  • The Company’s common stock will continue to trade under the symbol “ACOR,” and the new CUSIP number for the Company’s common stock following the reverse stock split is 00484M700.
  • Stockholders owning shares of common stock via a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to their brokers’ particular processes.

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Pharmaceutical, Health, Acorda Therapeutics, ACOR, Therapy, Special, Security (finance)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20.
  • The reverse stock split will apply equally to all outstanding shares of the common stock, and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares.
  • The reverse stock split will not modify the rights or preferences of the common stock.
  • As a result of the proportionate reduction in the number of authorized shares of common stock, the reverse stock split will result in the number of authorized shares of common stock being reduced from 61,666,666 to 3,083,333.

Acorda Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Science, Health, Neurology, Research, ACOR, Shareholder, SG, Senior, Q&A, Internet, Telephone, Biotechnology, Annual Meetings of the International Monetary Fund and the World Bank Group, Ageing, GAAP, Audit committee, Accounting, Burns, Annual general meeting, OPEX, Acorda Therapeutics, R, Therapy, Pharmaceutical industry, Video game, Bank, Finance, Chance, Açorda, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2023.
  • For the quarter ended March 31, 2023, the Company reported AMPYRA net revenue of $12.6 million, a 15.4% decrease compared to $14.9 million for the same quarter in 2022.
  • Additionally, for the quarter ended March 31, 2023, the Company reported FAMPYRA royalty revenues of $2.9 million, a 9.3% decrease compared to the same quarter in 2022.
  • Research and development (R&D) expenses for the quarter ended March 31, 2023 were $1.4 million, compared to $1.7 million for the same quarter in 2022.

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

Retrieved on: 
Wednesday, May 10, 2023
Biotechnology, General Health, Neurology, Health, Pharmaceutical, Acorda Therapeutics, Note, ACOR, Therapy, Senior, Security (finance), Bookkeeping, Indenture

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture.
  • Under the terms of the Indenture, Acorda may elect to make interest payments under the Indenture in cash or shares of the Company’s common stock.
  • The Company will make the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Company’s balance sheet as restricted cash.
  • By making this interest payment in cash, the Company has ensured that there will be no dilution to shareholders as a result of this payment.